Peanut agglutinin shows specificity for bone marrow plasma cells

Area of Science:

• Immunology
• Hematology
• Biochemistry

Background:

• Multiple myeloma is a cancer of plasma cells.
• Effective treatment often involves high-dose chemotherapy and autologous stem cell transplantation.
• Identifying agents for ex vivo bone marrow purging is crucial to eliminate residual myeloma cells.

Purpose of the Study:

• To investigate the potential of peanut agglutinin (PNA) as an agent for in vitro bone marrow purging in multiple myeloma.
• To analyze surface carbohydrate expression on myeloma cells using lectin binding.

Main Methods:

• A panel of lectins, including PNA, was used to probe bone marrow samples.
• PNA binding was assessed on plasma cells and other mononuclear cells from myeloma patients, individuals with monoclonal gammopathy of undetermined significance, and healthy donors.
• Sialidase treatment was employed to evaluate changes in lectin binding.

Main Results:

• Peanut agglutinin (PNA) demonstrated strong binding to plasma cells in the majority of myeloma and monoclonal gammopathy bone marrow samples.
• Monocytes showed weak PNA reactivity, with exceptions in specific leukemia subtypes.
• PNA did not bind to the single case of plasma cell leukemia studied.
• Other bone marrow mononuclear cells became PNA-positive after sialidase treatment.

Conclusions:

• Peanut agglutinin exhibits specific binding to myeloma plasma cells, suggesting its potential utility in ex vivo bone marrow purging.
• PNA may serve as a valuable adjunct to high-dose chemotherapy for autologous transplantation in multiple myeloma patients.
• Further validation is required to establish PNA's role in clinical myeloma therapy.